SynAct Pharma AB (8F8) Stock Statistics & Valuation Metrics
Total Valuation
SynAct Pharma AB has a market cap or net worth of EUR 82.81M. The enterprise value is EUR 1.17B.
- Market Cap
- EUR 82.81M
- Enterprise Value
- EUR 1.17B
Share Statistics
SynAct Pharma AB has 56,213,966 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 56,213,966
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
SynAct Pharma AB’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -54.66%.
- Return on Equity (ROE)
- -0.65
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -54.66%
- Return on Capital Employed (ROCE)
- -0.59
- Revenue Per Employee
- 0
- Profits Per Employee
- -13.85M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of SynAct Pharma AB is -8.23. SynAct Pharma AB’s PEG ratio is -12.87.
- PE Ratio
- -8.23
- PS Ratio
- 0.00
- PB Ratio
- 5.31
- Price to FCF
- -10.99
- Price to Operating Cash Flow
- -7.78
- PEG Ratio
- -12.87
Income Statement
In the last 12 months, SynAct Pharma AB had revenue of 0 and earned -110.83M in profits. Earnings per share was -2.17.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -117.15M
- Pretax Income
- -118.99M
- Net Income
- -110.83M
- EBITDA
- -116.52M
- Earnings Per Share (EPS)
- -2.17
Cash Flow
In the last 12 months, operating cash flow was -117.21M and capital expenditures 34.54M, giving a free cash flow of -82.67M billion.
- Operating Cash Flow
- -117.21M
- Free Cash Flow
- -82.67M
- Free Cash Flow per Share
- -1.47
Dividends & Yields
SynAct Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.10%
- Earnings Yield
- -11.64%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -30.12%
- 50-Day Moving Average
- 1.60
- 200-Day Moving Average
- 1.61
- Relative Strength Index (RSI)
- 39.61
- Average Volume (3m)
- ―
Important Dates
SynAct Pharma AB upcoming earnings date is Nov 03, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Nov 03, 2026
- Ex-Dividend Date
- ―
Financial Position
SynAct Pharma AB as a current ratio of 3.31, with Debt / Equity ratio of 1.06%
- Current Ratio
- 3.31
- Quick Ratio
- 3.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.44
- Interest Coverage Ratio
- -47.80
Taxes
In the past 12 months, SynAct Pharma AB has paid -8.16M in taxes.
- Income Tax
- -8.16M
- Effective Tax Rate
- 0.07
Enterprise Valuation
SynAct Pharma AB EV to EBITDA ratio is -7.94, with an EV/FCF ratio of -10.83.
- EV to Sales
- 0.00
- EV to EBITDA
- -7.94
- EV to Free Cash Flow
- -10.83
- EV to Operating Cash Flow
- -7.64
Balance Sheet
SynAct Pharma AB has EUR 14.23M in cash and marketable securities with EUR 929.00K in debt, giving a net cash position of EUR 13.30M billion.
- Cash & Marketable Securities
- EUR 14.23M
- Total Debt
- EUR 929.00K
- Net Cash
- EUR 13.30M
- Net Cash Per Share
- EUR 0.24
- Tangible Book Value Per Share
- EUR 0.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for SynAct Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -1.52%